Evidence map›Paper›PMID 30847305›Full record

ArticleFrontiers in oncology2019

Wheat Germ Agglutinin as a Potential Therapeutic Agent for Leukemia.

Bradley Ryva, Keman Zhang, Abhishek Asthana, Derek Wong, Yorleny Vicioso, Reshmi Parameswaran

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. The growth and pathogenesis ofInfection and immunity · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Neuraminidase inhibition improves endothelial function in diabetic mice.American journal of physiology. Heart and circulatory physiology · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Bradley RyvaDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, United States.
Keman ZhangDivision of Hematology/Oncology, Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, United States.
Abhishek AsthanaDivision of Hematology/Oncology, Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, United States.
Derek WongDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, United States.
Yorleny ViciosoDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, United States.
Reshmi ParameswaranDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, United States.
Case Western Reserve University · US

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
NRSA Training CoreTL1TR002549 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI HARDING, CLIFFORD V · 2018 to 2022
$2.9M
Targeting B cell activating factor receptor (BAFF-R) as a novel therapeutic strategy for drug resistant Acute Lymphoblastic Leukemia (ALL)R21CA201775 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI PARAMESWARAN, RESHMI · 2016 to 2017
$379k
NCATS NIH HHS TL1 TR002549NCI NIH HHS P30 CA043703NCI NIH HHS R21 CA201775NIGMS NIH HHS T32 GM007250
6 · The paper itself

Abstract

Dietary lectins are carbohydrate-binding proteins found in food sources. We used a panel of seven dietary lectins to analyze cytotoxicity against hematological cancers. Wheat germ agglutinin (WGA), even at low doses, demonstrated maximum toxicity toward acute myeloid leukemia (AML) cells. Using AML cell lines, we show time- and dose-dependent killing by WGA. We also show that low doses of WGA kills primary patient AML cells, irrespective of subtype, with no significant toxicity to normal cells. WGA caused AML cell agglutination, but failed to agglutinate RBC's at this dose. WGA, primarily, binds to

Indexed as

GlcNAclectinleukemiatherapyWGA

Identifiers

PMID30847305
PMCPMC6393371
OpenAlexW2915526534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.